Clinical trials: Tuberculosis Infection
Latent Tuberculosis, Active Tuberculosis
Improving the Detection of Active Tuberculosis in Accident and Emergency Departments
Tuberculosis (TB) control remains a public health challenge. Many people in the UK do not have a general practitioner (GP) registration and their only interaction with the NHS is via Accident and Emergency (A\&E) Departments of…
- Trial name
- ACE (NCT02512484)
- Testing
- venepuncture, sputum collection, xray
- Where
- 3 sites in United Kingdom
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Public Health England
Tuberculosis, Pulmonary, Rifampicin Resistant Tuberculosis
GeneXpert Performance Evaluation for Linkage to Tuberculosis Care
The investigators' overall objective is to assess the effectiveness, implementation and costs of a streamlined TB diagnostic evaluation strategy based around rapid, onsite molecular testing.
- Trial name
- XPEL-TB (NCT03044158)
- Testing
- GeneXpert I, Process re-design, Performance Feedback
- Where
- 20 sites in Uganda
- Volunteers
- 10,644 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Tuberculosis
Phase 1 Study of PBTZ169
Open-label prospective non-comparative safety, tolerability and pharmacokinetics ascending dose randomized cohort study of PBTZ169 (capsules 40 mg) in fasted healthy volunteers after single and multiple oral administration
- Trial name
- NCT03036163
- Testing
- PBTZ169 - 40 mg, PBTZ169 - 80 mg, PBTZ169 - 160 mg
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Nearmedic Plus LLC
Human Immunodeficiency Virus, Tuberculosis
Usability Study of IeHS in Indonesia
Technology that has a particular focus on patients' needs and ease-of-use and -access plays a significant role in the development of e-health and m-health.
- Conditions
- Human Immunodeficiency Virus, Tuberculosis, Interpersonal Relations, Mobile Phone Use
- Trial name
- NCT04179344
- Testing
- Integrated e-healthcare services (IeHS) web-based app
- Where
- 3 sites in Indonesia
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Bekasi City Public Hospital
Tuberculosis, Tuberculosis Vaccines
Study to Evaluate the Efficacy of GlaxoSmithKline (GSK) Biologicals' Candidate Tuberculosis (TB) Vaccine in Adults
The purpose of this study is to evaluate the protective efficacy of two doses of GSK Biologicals' candidate TB vaccine against pulmonary TB, as compared to placebo.
- Trial name
- NCT01755598
- Testing
- GSK Biologicals' investigational TB vaccine (GSK692342)
- Where
- 9 sites in Kenya, South Africa and 1 more
- Volunteers
- 3,575 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Tuberculosis
Safety and Immunogenicity of MVA85A in Volunteers Latently Infected With TB.
This study is designed to evaluate the safety of MVA85A in healthy volunteers in the UK who are latently infected with M.tb. A single vaccination with MVA85A, when administeredat a dose of 5 x 107pfu intradermally, is safe in…
- Trial name
- NCT00456183
- Testing
- MVA 85A
- Where
- United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Tuberculosis
A Knowledge Translation Intervention for TB/HIV Treatment Adherence, in Zomba District, Malawi
Despite increased emphasis on evidence based practice in recent years a gap remains between evidence and practice, particularly in resource poor countries.
- Trial name
- NCT01356095
- Testing
- Knowledge translation intervention, Palm-Plus
- Where
- Malawi
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Dignitas International
HIV Primary Infection
Diagnostic Performance of a Novel Lipoarabinomannan.
The Fujifilm SILVAMP TB LAM (FujiLAM; Fujifilm, Tokyo, Japan) is a novel (not commercialized) urine based point-of-care assay to diagnose TB in HIV-positive patients.
- Trial name
- FUJILAM (NCT05036694)
- Testing
- FUJILAM KIT
- Volunteers
- 550 people, healthy volunteers welcome
- Sponsor
- Médecins Sans Frontières, Kenya
Tuberculosis, Hiv
Kharituwe TB Contact Tracing Study
The purpose of this study is to characterize the role of human mobility in fueling TB epidemics and estimate the potential impact of innovative case finding interventions tailored to mobile populations
- Trial name
- NCT04520113
- Testing
- Household contact tracing
- Where
- 2 sites in South Africa
- Volunteers
- 10,579 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Opioid Dependency, HIV Infections
Interaction of Buprenorphine With HIV Medications and Tuberculosis Medications
The purpose of this study is to examine the interactions of buprenorphine-naloxone, a medication used to treat opiate (heroin or prescription narcotic) dependence, and medications used in the treatment of HIV disease including…
- Trial name
- NCT00877591
- Testing
- Fosamprenavir/Ritonavir, Darunavir/Ritonavir, Rifampin
- Where
- United States
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
All Cause Mortality, Cardiovascular Diseases
Advice of Moderate Drinking Pattern Versus Advice on Abstention on Major Disease and Mortality
The goal of this clinical trial is to test two advices on alcohol drinking in more than 10.000 Spanish adult drinkers (men of 50 or more years and women of 55 or more years).
- Conditions
- All Cause Mortality, Cardiovascular Diseases, Invasive Cancer, Liver Cirrhosis
- Trial name
- UNATI (NCT06338215)
- Testing
- Moderate Alcohol Drinking Pattern, Abstention
- Where
- Spain
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Clinica Universidad de Navarra, Universidad de Navarra
Tuberculosis
Safety and Immunogenicity Study of a Candidate Tuberculosis Vaccine in Healthy Infants
This purpose of the study is to assess the safety and immunogenicity of a GSK Biologicals' candidate tuberculosis vaccine (692342) when administered concomitantly with or after the Expanded Programme of Immunisation vaccines…
- Trial name
- NCT01098474
- Testing
- GSK's investigational vaccine 692342, Tritanrix™ HB+Hib, Prevnar™
- Where
- The Gambia
- Volunteers
- 301 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Latent Tuberculosis Infection
Phase IV Clinical Study of Recombinant Mycobacterium Tuberculosis Fusion Protein
Cohort 1 was a randomized, double-blind, controlled clinical trial with a planned enrollment of 500 patients. Cohort 2 is a non-randomized, open-label clinical trial with a planned enrollment of approximately 60000 patients.
- Trial name
- NCT05746611
- Testing
- Recombinant Mycobacterium tuberculosis fusion protein for injection, TB-PPD was injected
- Where
- China
- Volunteers
- 7,500 people, healthy volunteers welcome
- Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
Tuberculosis (TB)
Effectiveness of Computer-Aided Detection Chest X-Ray Screening for Improving Tuberculosis Diagnostic Yield in Chinese Primary Health Care Settings: Study Protocol for a Prospective Cluster Randomized Controlled Trial
The global incidence rate and mortality of tuberculosis (TB) pose a challenge to achieving the goals set out in the tuberculosis eradication strategy and the SDGs by 2030.
- Trial name
- NCT06963606
- Testing
- Artificial intelligence-assisted chest X-ray in TB screening, Routine doctors analyze the process of chest X-rays
- Where
- China
- Volunteers
- 22,000 people, healthy volunteers welcome
- Sponsor
- Xuelin Yang
COVID-19, Lung Cancer
Perioperative Outcomes of Anatomic Lung Resections in Patients Who Recovered From Coronavirus Disease 2019
This study will determine the outcomes of anatomic lung resections in patients who recovered from coronavirus disease 2019 (COVID-19) disease by describing the morbidity and mortality as well as the length of postoperative…
- Conditions
- COVID-19, Lung Cancer, Lung TB, Hemoptysis
- Trial name
- NCT05513248
- Testing
- anatomic lung resection
- Where
- Philippines
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Lung Center of the Philippines
Reducing Tuberculosis Incidence
DeMONSTRATE-TB Study in Ethiopia
Ending the TB epidemic by 2035 in Ethiopia would be possible if TB notification declines by an annual factor of at least 15% from the current notification rate of 132 per 100,000 population.
- Trial name
- NCT06719193
- Testing
- Enhanced community-wide TB intervention, Routine TB program activities
- Where
- 2 sites in Ethiopia
- Volunteers
- 131,438 people, healthy volunteers welcome
- Sponsor
- Management Sciences for Health
Tuberculosis, COVID-19
Evaluating the Impact of Computer-assisted X-ray Diagnosis and Other Triage Tools to Optimise Xpert Orientated Community-based Active Case Finding for TB and COVID-19
Tuberculosis (TB) is now the commonest cause of death in many African countries. Globally, ~35% (almost 1 in 3) of TB cases are 'missed' (remain undiagnosed or undetected).
- Conditions
- Tuberculosis, COVID-19, HIV Infections
- Trial name
- NCT05220163
- Testing
- CAD, Xpert
- Where
- 3 sites in South Africa, Zambia and 1 more
- Volunteers
- 26,200 people, healthy volunteers welcome
- Sponsor
- University of Cape Town
Tuberculosis Identification.
Equivalence Study of Tuberculin Purified Protein Derivative in Comparison With a Reference Standard (PPD-S2)
A study to determine bioequivalence of PPD material versus Reference Standard.
- Trial name
- 02 (NCT01798121)
- Testing
- To compare new PPD to reference standard material, Reference standard
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- JHP Pharmaceuticals LLC
Tuberculosis
A Phase I Randomized Placebo-Controlled, Double-Blind Study to Evaluate Safety and Immunogenicity of AERAS-404 Administered as Different Amounts of Antigen and Adjuvant Combinations in HIV-Negative BCG-Vaccinated Adults Without Evidence of Tuberculosis Infection
Phase I, randomized, double blinded, Placebo-controlled, immunogenicity and dose-range finding study of AERAS-404 in Bacille Calmette-Guerin (BCG) healthy adult male and sterile females.
- Trial name
- NCT02066428
- Testing
- AERAS-404
- Where
- Sweden
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Aeras
Tuberculosis
A Phase I Study of the Safety and Immunogenicity of a Recombinant MVA Vaccine Encoding a Secreted Antigen From M. Tuberculosis, Antigen 85A, Delivered Intradermally by a Needle Injection in Healthy Volunteers Who Have Previously Received BCG
This is a phase I study to examine the safety and immunogenicity of MVA85A delivered intradermally into the deltoid region in volunteers who have recieved BCG in the past 20 years.
- Trial name
- NCT00427830
- Testing
- MVA85A
- Where
- United Kingdom
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- University of Oxford